Article

Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switching

2019-12-03

Abstract excerpt

Anti-BRAF plus anti-MEK are used as first-line treatment of patients with metastatic melanomas harboring BRAF V600E mutation. The main issue with targeted therapy is acquired cellular resistance. In 70% of acquired resistance, melanoma cells switch their phenotype and become more aggressive and invasive. The molecular signature of this phenotype is MITF low, AXL high associated with actin cytoskeleton reorganizat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ada434c2-e3a3-53a7-b167-69df5593fc05
DOI: 10.1101/857904

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switchingDOI 10.1101/857904Read

Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.Semantic proximity Read

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapySemantic proximity Read

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read

Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell linesSemantic proximity Read

Transcriptional reprogramming and constitutive PD-L1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumor necrosis factor signaling pathwaysSemantic proximity Read

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.Semantic proximity Read

Discoidin domain receptors: A promising target in melanomaSemantic proximity Read

Src-dependent DBL family members drive resistance to vemurafenib in human melanomaSemantic proximity Read

Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.Semantic proximity Read

Phenotype Switching in Melanoma: Implications for Progression and TherapySemantic proximity Read

Phenotype characterization of human melanoma cells resistant to dabrafenib.Semantic proximity Read

Adaptive resistance to <scp>RAF</scp> inhibitors in melanomaSemantic proximity Read